Company Overview of Capital International, Inc.
Capital International, Inc. is a privately owned investment manager. The firm primarily provides its services to individuals, corporate and public pension plans and profit sharing plans, pooled investment vehicles, foreign governmental entities, investment companies, corporations, state or municipal government entities, and institutions in Asia, Australia, and New Zealand. It manages client specific portfolios and investment funds for its clients. The firm invests in the public equity, fixed income, and private equity markets across the globe. Its equity investments includes of growth stocks. The firm’s fixed income investments include investment grade securities of governmental, supranation...
11100 Santa Monica Boulevard
Los Angeles, CA 90025-3384
Founded in 1987
Key Executives for Capital International, Inc.
President, Portfolio Manager, and Director
Co-Founder, Senior Vice President, Research Director for Private Equity, Private Equity Senior Managing Partner, Director, and Vice Chairman of the Investment Committee
Managing Partner and Member of Investment Committee
Compensation as of Fiscal Year 2015.
Capital International, Inc. Key Developments
Capital International, Inc. Presents at 16th Annual Global Private Equity Conference, May-13-2014 09:15 AM
Mar 21 14
Capital International, Inc. Presents at 16th Annual Global Private Equity Conference, May-13-2014 09:15 AM. Venue: Ritz-Carlton, Washington, District Of Columbia, United States. Speakers: Koenraad Carl Alice Foulon, Senior Vice President, Private Equity Senior Managing Partner, Director, and the Chairman of the Investment Committee.
Investors Reportedly Eyes Stake In Intas
Jan 29 14
Temasek Capital, GIC Pte. Ltd., and Capital International, Inc. are in independent talks to purchase ChrysCapital's 10% stake in Intas Pharmaceuticals Ltd. for about $150 million, three people with direct knowledge of the development said. An investment banker said, "Chrys-Capital is looking to sell part of its 16.5% stake after Intas Pharma postponed its initial public offering due to muted market conditions." "Yes, ChrysCapital is looking for partial exit from the company and the IPO plan was also formulated with the objective of providing exit," Jayesh Shah, Chief Financial Officer of Intas Pharma said in an email response. "However, Intas is still evaluating various options to provide meaningful exit to ChrysCapital and nothing has been concretised so far." Another person familiar with the matter said, "Along with the partial exit of the existing investor, the promoters could look at raising fresh funds for the company." "No valuation number has been frozen," said Shah of Intas.
Balaji Wafers Is In Talks With Investors For 10% Stake Sale
Dec 9 13
Balaji Wafers Pvt. Ltd. has decided to sell a 10% stake, nearly five months after it began talks with strategic investors to sell a majority stake. Capital International, Inc. and Actis Capital, LLP have emerged as the frontrunners to buy the stake. “We are in talks with these two companies and some others as well,” Balaji Wafers Managing Director Chandubhai Virani said. “We are looking at divesting about a 10% stake and would like to set up new factories with the funds that we raise in the process.” According to Live Mint, J.M. Trivedi, Partner and head of South Asia at Actis, said, “We do not comment on market speculation.” According to Live Mint, an email sent to the media relations team at Capital International on December 6, 2013 did not elicit a response by December 9, 2013. Virani said the promoters were not keen on giving away control of the snacks maker. The exact size of the stake sale could be negotiated, but it would be a minority holding, he said, adding that the process could take another four to six months. The company has mandated consulting fiadrm EY for the transaction. Pepsico, Inc. (NYSE:PEP) is among suitors exploring a bid for Balaji Wafers, Bloomberg reported in August 2013. “The Virani family plans to sell up to a 49% stake for as much as $300 million,” the report said, citing a person familiar with the matter who didn’t want to be named. Balaji Wafers, with revenue of about INR 9 billion in the year ended March 31, 2012, plans to increase sales to INR 15 billion by 2015, Keyur Virani, a director of Balaji Wafers, told Mint in July. The valuation of the brand is about INR 35-40 billion, he claimed.
Similar Private Companies By Industry
Recent Private Companies Transactions